SCHEMBL4423615

SCHEMBL4423615

CCOC(=O)C(C)C(=O)OCC.CN1CCc2ccccc2C(N)C1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.52
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
OPRM1 P35372 3/20 0.39
OPRK1 P41145 3/20 0.39
OPRD1 P41143 1/20 0.38
ACE P12821 1/20 0.38
NOTUM Q6P988 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122057 0.83 XIAP (0.54) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4122465 0.83 XIAP (0.54) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4126331 0.83 XIAP (0.54) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4941575 0.81 XIAP (0.54) XIAPPSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL4114257 0.81 XIAP (0.53) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4941582 0.75 XIAP (0.44) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4941581 0.73 OPRM1 (0.44) XIAPPSEN1PSEN2APH1BNCSTN
SCHEMBL4121058 0.71 PRCP (0.46) XIAPALDH1A1KMT2AMEN1OPRM1
SCHEMBL4120258 0.71 PRCP (0.46) XIAPALDH1A1KMT2AMEN1OPRM1
SCHEMBL4116682 0.71 PRCP (0.46) XIAPALDH1A1KMT2AMEN1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711470-B1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE HOFFMANN LA ROCHE (CH) 2009-04-15 EP disclosed
US-7160875-B2 Malonamide derivatives HOFFMANN-LA RACHE INC. (US) 2007-01-09 US disclosed
EP-1711470-A1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE F. HOFFMANN-LA ROCHE AG (CH) 2006-10-18 EP disclosed
WO-2005023772-A1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE F. HOFFMANN-LA ROCHE AG (CH) 2005-03-17 WO disclosed
US-20050054633-A1 secretase inhibitors; therapy for Alzheimer's disease HOFFMANN-LA ROCHE INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054633-A1 secretase inhibitors; therapy for Alzheimer's disease BACE1, BACE2, APP XIAP 3379/4885PSEN1 6/4885PSEN2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.